The prognosis of chronic aggressive hepatitis. A clinical and morphological follow-up study.

In a follow-up study of 85 patients with chronic aggressive (active) hepatitis (CAH) repeated liver biopsies and/or autopsy liver sections were available in 74 cases. The median time of observation was 45 months. Cirrhosis was demonstrated in 38 patients, and cirrhosis was suspected in a further five cases. Fifteen patients showed convincing histological improvement; and the remaining 16 still had chronic hepatitis. Twenty-six patients died during the observation period, seven of these of liver failure after development of cirrhosis. The clinical follow-up of the 59 survivors (median observation time 69 months) showed biochemically active liver disease in 11 cases, all having cirrhosis or chronic aggressive hepatitis in the last biopsy. The clinical findings were correlated with the morphological follow-up diagnosis and the immunosuppressive treatment. Comparison of the initial histological, clinical, and serological variables was made in two well-defined follow-up groups. There were more females, and marked portal inflammation, abnormal bile duct epithelium, and circulating autoantibodies occurred more frequently in the group with later development of cirrhosis than among the patients with subsequent morphological improvement. The results thus suggest candidates for thorough follow-up and more intensive immunosupressive or other treatment.

[1]  J. Boyer,et al.  Chronic hepatitis--a perspective on classification and determinants of prognosis. , 1976, Gastroenterology.

[2]  W. Summerskill,et al.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. , 1975, Gut.

[3]  O. Dietrichson Chronic persistent hepatitis. A clinical, serological, and prognostic study. , 1975, Scandinavian journal of gastroenterology.

[4]  W. Summerskill Chronic active liver disease reexamined: prognosis hopeful. , 1974, Gastroenterology.

[5]  S. Phillips,et al.  Inhibition of colonic water and electrolyte absorption by fatty acids in man. , 1973, Gastroenterology.

[6]  R. Stern,et al.  Controlled trial of prednisone and azathioprine in active chronic hepatitis. , 1973, Lancet.

[7]  L. Elveback,et al.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. , 1972, Gastroenterology.

[8]  S. Sherlock,et al.  Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. , 1971, The Quarterly journal of medicine.

[9]  J. Boyer,et al.  Pattern of necrosis in acute viral hepatitis. Prognostic value of bridging (subacute hepatic necrosis). , 1970, The New England journal of medicine.

[10]  S. Sherlock,et al.  Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. , 1970, Lancet.

[11]  C. Blackburn,et al.  Active chronic hepatitis. , 1970, The American journal of medicine.

[12]  E. Wildhirt,et al.  [Prognosis of chronic hepatitis. 1. Forms and developmental stages]. , 1969, Deutsche medizinische Wochenschrift.

[13]  J. de Groote,et al.  A classification of chronic hepatitis. , 1968, Lancet.

[14]  O. Dietrichson Chronic active hepatitis. Aetiological considerations based on clinical and serological studies. , 1975, Scandinavian journal of gastroenterology.

[15]  A. Read,et al.  ACTIVE 'JUVENILE' CIRRHOSIS CONSIDERED AS PART OF A SYSTEMIC DISEASE AND THE EFFECT OF CORTICOSTEROID THERAPY. , 1963, Gut.